Relmada Therapeutics Valuation

RLMD Stock  USD 2.90  0.18  6.62%   
Based on Macroaxis valuation methodology, the company appears to be undervalued. Relmada Therapeutics holds a recent Real Value of $4.66 per share. The prevailing price of the company is $2.9. Our model determines the value of Relmada Therapeutics from analyzing the company fundamentals such as Shares Owned By Institutions of 46.06 %, return on equity of -1.0, and Shares Outstanding of 30.17 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Relmada Therapeutics' valuation include:
Price Book
1.8374
Enterprise Value
33.4 M
Enterprise Value Ebitda
0.5431
Undervalued
Today
2.90
Please note that Relmada Therapeutics' price fluctuation is relatively risky at this time. Calculation of the real value of Relmada Therapeutics is based on 3 months time horizon. Increasing Relmada Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Relmada stock is determined by what a typical buyer is willing to pay for full or partial control of Relmada Therapeutics. Since Relmada Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Relmada Stock. However, Relmada Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  2.9 Real  4.66 Target  10.38 Hype  2.86
The real value of Relmada Stock, also known as its intrinsic value, is the underlying worth of Relmada Therapeutics Company, which is reflected in its stock price. It is based on Relmada Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Relmada Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
4.66
Real Value
8.64
Upside
Estimating the potential upside or downside of Relmada Therapeutics helps investors to forecast how Relmada stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Relmada Therapeutics more accurately as focusing exclusively on Relmada Therapeutics' fundamentals will not take into account other important factors:
Earnings
Estimates (0)
LowProjectedHigh
0.000.000.00
Details
Hype
Prediction
LowEstimatedHigh
0.142.866.84
Details
4 Analysts
Consensus
LowTarget PriceHigh
9.4510.3811.52
Details
Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Relmada Therapeutics' intrinsic value based on its ongoing forecasts of Relmada Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Relmada Therapeutics' closest peers. If more than one evaluation category is relevant for Relmada Therapeutics we suggest using both methods to arrive at a better estimate.

Relmada Therapeutics Cash

3.89 Million

Relmada Valuation Trend

Comparing Relmada Therapeutics' enterprise value against its market capitalization is a good way to estimate the value of Relmada Therapeutics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.

Relmada Therapeutics Total Value Analysis

Relmada Therapeutics is at this time expected to have valuation of 33.39 M with market capitalization of 87.51 M, debt of 12.19 M, and cash on hands of 211.96 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Relmada Therapeutics fundamentals before making equity appraisal based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
33.39 M
87.51 M
12.19 M
211.96 M

Relmada Therapeutics Asset Utilization

One of the ways to look at asset utilization of Relmada is to check how much profit was generated for every dollar of assets it reports. Relmada Therapeutics holds a negative application of assets of -0.59 pct., losing $0.005913 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Relmada Therapeutics shows how discouraging it operates for each dollar spent on its assets.
 
Yuan Drop
 
Covid

Relmada Therapeutics Ownership Allocation

Relmada Therapeutics owns a total of 30.17 Million outstanding shares. 30% of Relmada Therapeutics outstanding shares are owned by third-party entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.

Relmada Therapeutics Profitability Analysis

Net Loss for the year was (98.79 M) with profit before overhead, payroll, taxes, and interest of 0.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Relmada Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Relmada Therapeutics and how it compares across the competition.

About Relmada Therapeutics Valuation

The stock valuation mechanism determines Relmada Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Relmada Therapeutics. We calculate exposure to Relmada Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Relmada Therapeutics's related companies.
Last ReportedProjected for Next Year
Gross Profit-1.1 K-1.2 K
Pretax Profit Margin(1.75)(1.83)
Operating Profit Margin(1.75)(1.83)
Net Loss(1.75)(1.83)
Gross Profit Margin 0.31  0.26 

Relmada Therapeutics Growth Indicators

Investing in growth stocks can be very risky. If the company such as Relmada Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Common Stock Shares Outstanding30.1 M

Relmada Therapeutics Current Valuation Indicators

Valuation refers to the process of determining the present value of Relmada Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Relmada we look at many different elements of the entity such as Relmada's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Relmada Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Relmada Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Relmada Therapeutics' worth.

Complementary Tools for Relmada Stock analysis

When running Relmada Therapeutics' price analysis, check to measure Relmada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relmada Therapeutics is operating at the current time. Most of Relmada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relmada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relmada Therapeutics' price. Additionally, you may evaluate how the addition of Relmada Therapeutics to your portfolios can decrease your overall portfolio volatility.
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators